| Name | Title | Contact Details |
|---|
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAb™ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.
Verinetics is a company that provides the DispenSecur solution for Opioid Medication Management, which offers better control for controlled substances and integrates into existing pharmacy and patient management practices.
A clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases.
Learn about who we are, our approach to scientific innovation, our areas of therapeutic focus, our products, commitments and more.